文献库搜索 | GeneLibs

Zhang(K),Chen(T),Wu(X),Wu(R),Chen(B),Shi(J... Pathol Res Pract 2026-05-00

...ALK. MCL1 amplification was observed in two cases, suggesting activation of anti-apoptotic pathways CONCLUSIONS: RenNETs...

Chu(D),Han(H),Wei(C),Zhang(X),Yan(H),Wang(... Bioorg Chem 2026-06-05

...ALK kinase inhibition assay, B-6, B-7, B-9, and B-10 retained potent ALK kinase inhibition (IC50 = 0.74-1.24 nM), which ...

Mittenbacher(N),Philippi(JC),Vordermark(D)... Radiat Oncol 2026-02-24

...ALK mutation status, and PD-L1 expression. Due to the low number of non-adenocarcinoma (NAC) cases in our cohort, only p...

Cheng(W),Qiao(G),Zhang(W),Song(Y),Zan(X) Respirol Case Rep 2026-02-00

...ALK-negative but subsequently developed an ALK fusion following chemotherapy. A 52-year-old female was diagnosed with ad...

Gumma(L),Gumma(B),Yarrabothula(LP) Naunyn Schmiedebergs Arch P... 2026-04-00

...ALK inhibitor, with crizotinib in patients with advanced ALK-rearranged NSCLC who had not received prior ALK-targeted th...

Tunbekici(S),Bal(H),Kınıkoglu(O),Arvas(H),... Clin Transl Oncol 2026-08-00

Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor, has demonstrated efficacy in p...

Al Tawil(A),Lauseker(M),Mansmann(U) J Clin Epidemiol 2026-05-00

...ALK + non-small-cell lung cancer), integrating both frameworks. Following Young et al's (2020) causal framework for comp...

Gandy(L),Tilli(F) Cancer Inform None

...ALK, BRAF, EGFR, ERBB2, KIT, and KRAS). The results demonstrate good F1-scores for both LLMs-averaging 64% for GPT-4.0 a...

Piccaluga(PP),Cimmino(L),Tsekhovska(V),Cim... Cells 2026-02-19

...ALK fusions) conducive to immortalization. Conversely, the majority of peripheral T-cell lymphoma (PTCL) subtypes, which...

Shumilov(E),Ngoya(M),Berning(P),Khvedelidz... Hemasphere 2026-02-00

...ALK-negative ALCL undergoing auto-SCT between 2010 and 2022 and reported to EBMT. Adult patients with major T-cell entit...